|
May 6
|
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
|
|
Apr 24
|
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
|
|
Apr 10
|
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
|
|
Apr 8
|
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
|
|
Apr 2
|
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
|
|
Mar 11
|
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
|
|
Mar 5
|
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
|
|
Dec 20
|
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
|
|
Dec 4
|
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
|
|
Nov 27
|
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
|
|
May 22
|
RedHill Provides R&D Update
|